NO942323L - Soy protein or hydrolysates in pharmaceutical compositions for the protection of bioactive peptides against enzymatic inactivation - Google Patents

Soy protein or hydrolysates in pharmaceutical compositions for the protection of bioactive peptides against enzymatic inactivation

Info

Publication number
NO942323L
NO942323L NO942323A NO942323A NO942323L NO 942323 L NO942323 L NO 942323L NO 942323 A NO942323 A NO 942323A NO 942323 A NO942323 A NO 942323A NO 942323 L NO942323 L NO 942323L
Authority
NO
Norway
Prior art keywords
hydrolysates
protection
pharmaceutical compositions
enzymatic inactivation
soy protein
Prior art date
Application number
NO942323A
Other languages
Norwegian (no)
Other versions
NO942323D0 (en
Inventor
Gordon L Amidon
Glen D Leesman
Patrick J Sinko
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO942323D0 publication Critical patent/NO942323D0/en
Publication of NO942323L publication Critical patent/NO942323L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Proteiner eller peptider som kan fremstilles fra naturlig forekommende proteiner, oker biotilgjengeligheten til proteolytisk labile, terapeutiske midler som, i fravær av protein- eller peptid-stoffet, ville utsettes for enzymatisk inaktivering ved administrering.Proteins or peptides that can be prepared from naturally occurring proteins increase the bioavailability of proteolytically labile therapeutic agents which, in the absence of the protein or peptide substance, would be subjected to enzymatic inactivation upon administration.

NO942323A 1991-12-18 1994-06-17 Soy protein or hydrolysates in pharmaceutical compositions for the protection of bioactive peptides against enzymatic inactivation NO942323L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81059391A 1991-12-18 1991-12-18
PCT/US1992/009336 WO1993011799A1 (en) 1991-12-18 1992-11-09 Soybean protein or hydrolyzates in pharmaceutical compositions to protect bioactive peptides from enzymatic inactivation

Publications (2)

Publication Number Publication Date
NO942323D0 NO942323D0 (en) 1994-06-17
NO942323L true NO942323L (en) 1994-06-17

Family

ID=25204183

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942323A NO942323L (en) 1991-12-18 1994-06-17 Soy protein or hydrolysates in pharmaceutical compositions for the protection of bioactive peptides against enzymatic inactivation

Country Status (12)

Country Link
EP (1) EP0617626A1 (en)
JP (1) JPH06510796A (en)
AU (1) AU3058392A (en)
CA (1) CA2125400A1 (en)
FI (1) FI942938A0 (en)
HU (1) HUT69785A (en)
IL (1) IL104048A0 (en)
MX (1) MX9207407A (en)
NO (1) NO942323L (en)
PT (1) PT101135A (en)
WO (1) WO1993011799A1 (en)
ZA (1) ZA929761B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2145763A1 (en) * 1992-10-02 1994-04-14 William J. Curatolo Pharmaceutical compositions containing nonionic surfactants
AU7273494A (en) * 1993-09-01 1995-03-22 Pfizer Inc. Pharmaceutical compositions containing anionic surfactants
DE19530865A1 (en) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Active ingredient and agent for parenteral nutrition
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
NZ520238A (en) * 2000-01-27 2004-04-30 Peros Systemes Technologies In Composition for intestinal delivery
GB0015921D0 (en) * 2000-06-30 2000-08-23 Nat Biolog Standards Board Improvements in or relating to stabilisation of substances
CL2008001640A1 (en) * 2007-06-08 2008-11-07 Bergen Teknologioverforing As Use of hydroxyproline to prepare an alloy composition intended to promote the growth of an animal, such as fish, birds and mammals.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4774089A (en) * 1985-06-14 1988-09-27 Albion International, Inc. Stimulation of gonadotropic hormones with mineral mixtures containing amino acid chelates
MY103189A (en) * 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
GB2212062B (en) * 1987-11-13 1991-07-17 Isf Spa Pharmaceutical compositions containing a calcitonin and a glycyrrhizinate ab- sorption enhancer
EP0341661A3 (en) * 1988-05-11 1991-05-02 The Du Pont Merck Pharmaceutical Company Peptide-drug compositions containing alpha-aminoboronic acid derivatives
DD273980B5 (en) * 1988-07-12 1994-04-14 Berlin Chemie Ag Process for the preparation of insulin preparations for rectal use
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
DK546289D0 (en) * 1989-11-02 1989-11-02 Danochemo As carotenoid

Also Published As

Publication number Publication date
MX9207407A (en) 1993-06-01
EP0617626A1 (en) 1994-10-05
AU3058392A (en) 1993-07-19
WO1993011799A1 (en) 1993-06-24
JPH06510796A (en) 1994-12-01
FI942938A7 (en) 1994-06-17
ZA929761B (en) 1994-06-17
NO942323D0 (en) 1994-06-17
HUT69785A (en) 1995-09-28
CA2125400A1 (en) 1993-06-24
HU9401824D0 (en) 1994-09-28
IL104048A0 (en) 1993-05-13
PT101135A (en) 1994-03-31
FI942938L (en) 1994-06-17
FI942938A0 (en) 1994-06-17

Similar Documents

Publication Publication Date Title
ES2178000T3 (en) COMPOSITIONS AND METHODS TO TREAT INFECTIONS USING INDOLICIDINE ANALOGS.
BR0112666A (en) Peptides as inhibitors of hepatitis C virus ns3-serine protease
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EA199901031A1 (en) Derivatives of benzimidazole
CY1106769T1 (en) LYOPHILISABLE PHARMACEUTICAL COMPOSITION OF PHARMACEUTICAL DRUG FOR SIMULATION OF A DRUG, ESPECIALLY PROTEIN OR POLYPEPTIDE BASED
EP1440980A3 (en) Peptide analogs of human myelin basic protein
ATE435661T1 (en) COMPOSITIONS CONTAINING ADJUVANT QS-21 WITH POLYSORBATE OR CYCLODEXTRIN AS AID
FR2792202B1 (en) LUPINE PEPTIDE EXTRACT AND PHARMACEUTICAL OR COSMETIC OR NUTRACEUTICAL COMPOSITION COMPRISING SUCH EXTRACT
NO20010995D0 (en) Cytotoxic peptides modified with large or lipophilic residues
DE69937798D1 (en) PEPTIDES BASED ON THE SEQUENCE OF HUMAN LACTOFERRINE AND ITS APPLICATION
ATE144535T1 (en) PLATE BLOCKING PEPTIDES
PL371549A1 (en) Tolerogenic peptides from myelin basic protein
WO2004054607A3 (en) Stable therapeutic proteins
ATE234111T1 (en) THERAPEUTIC USES OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BLEEDING CAUSED BY TRAUMA
ATE211391T1 (en) USE OF HMG PROTEINS FOR THE PRODUCTION OF MEDICINAL PRODUCTS WITH CYTOTOXIC ACTION
NO942323L (en) Soy protein or hydrolysates in pharmaceutical compositions for the protection of bioactive peptides against enzymatic inactivation
CO5570658A2 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETES
DK525384D0 (en) FACTOR PREPARATION VIII FOR THE TREATMENT OF HAEMOFILI A INHIBITOR PATIENTS AND PROCEDURE FOR THE PREPARATION OF SUCH A PREPARATION
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
ATE69164T1 (en) MEDICATIONS FOR THE TREATMENT OF URAEMIA.
RU96120655A (en) COMPOSITION FOR PREVENTION AND TREATMENT OF FLU AND ARVI
EP1174439A3 (en) Compositions and methods for treating infections using analogues of indolicidin
NZ228208A (en) Eglin compounds (hurudin) and protease inhibitor pharmaceutical compositions
TR200002611T2 (en) Beta-lipotropin and its uses
ATE184287T1 (en) DERIVATIVES OF PEPTIDES THERAPEUTICALLY EFFECTIVE IN THE BLOOD CLOTTING CAScade, METHOD FOR THE PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME